Med Avail Holdings, Inc. MDVL
We take great care to ensure that the data presented and summarized in this overview for MedAvail Holdings, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in MDVL
Top Purchases
Top Sells
About MDVL
MedAvail Holdings, Inc., a technology-enabled retail pharmacy technology and services company, develops and commercializes self-service pharmacy, mobile application, kiosk, and drive-thru solutions in the United States and Canada. It operates in two segments, Retail Pharmacy Services and Pharmacy Technology. The company's MedCenter enables on-site pharmacy in medical clinics, retail store locations, employer sites with and without onsite clinics, and other location where onsite prescription dispensing is desired, as well as establishes an audio-visual connection to a live pharmacist enabling prescription drug dispensing to occur directly to a patient with real-time supervision by a pharmacist. It also owns and operates SpotRx, a retail pharmacy platform. As of December 31, 2021, the company had 81 MedCenter kiosks. MedAvail Holdings, Inc. is headquartered in Mississauga, Canada.
Insider Transactions at MDVL
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Sep 28
2023
|
Ramona Seabaugh Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
303
-19.87%
|
$1,515
$5.7 P/Share
|
Sep 01
2023
|
Ramona Seabaugh Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
680
+30.84%
|
-
|
Mar 21
2023
|
Ramona Seabaugh Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,287
-15.21%
|
$0
$0.31 P/Share
|
Mar 06
2023
|
Mark Edward Doerr Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
72,785
-27.84%
|
$0
$0.31 P/Share
|
Mar 03
2023
|
Mark Edward Doerr Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
20,773
-7.36%
|
$0
$0.33 P/Share
|
Mar 03
2023
|
Ramona Seabaugh Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,727
-23.74%
|
$0
$0.34 P/Share
|
Mar 01
2023
|
Mark Edward Doerr Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
282,259
+50.0%
|
-
|
Mar 01
2023
|
Ramona Seabaugh Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
28,333
+45.69%
|
-
|
Jul 01
2022
|
Redmile Group, LLC Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,639,117
+28.57%
|
$7,639,117
$1.06 P/Share
|
Jul 01
2022
|
Redmile Group, LLC Director |
BUY
Grant, award, or other acquisition
|
Indirect |
9,411,765
+21.38%
|
$9,411,765
$1.06 P/Share
|
Apr 04
2022
|
Abg Wtt Med Avail LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
14,117,646
+38.06%
|
$14,117,646
$1.06 P/Share
|
Apr 04
2022
|
Redmile Group, LLC Director |
BUY
Grant, award, or other acquisition
|
Indirect |
14,117,646
+35.91%
|
$14,117,646
$1.06 P/Share
|
Dec 31
2020
|
Abg Wtt Med Avail LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
12,670
+0.19%
|
$190,050
$15.0 P/Share
|
Dec 29
2020
|
Abg Wtt Med Avail LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
100
+0.0%
|
$1,400
$14.0 P/Share
|
Dec 28
2020
|
Abg Wtt Med Avail LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
7,107
+0.11%
|
$92,391
$13.98 P/Share
|
Dec 24
2020
|
Abg Wtt Med Avail LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
8,890
+0.13%
|
$115,570
$13.99 P/Share
|
Dec 23
2020
|
Abg Wtt Med Avail LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
21,700
+0.32%
|
$282,100
$13.99 P/Share
|
Dec 22
2020
|
Abg Wtt Med Avail LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
16,948
+0.25%
|
$220,324
$13.7 P/Share
|
Dec 21
2020
|
Abg Wtt Med Avail LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
16,277
+0.24%
|
$211,601
$13.31 P/Share
|
Dec 18
2020
|
Abg Wtt Med Avail LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
18,600
+0.28%
|
$241,800
$13.59 P/Share
|